Drug to lower brain pressure could treat blinding IIH headaches

March 13, 2023: Patients with ‘blinding’ headaches known as Idiopathic Intercranial Hypertension (IIH) could be treated with an injectable peptide used for type 2 diabetes, a new trial has found. The study, published in the journal Brain, reports on a phase two trial of a drug called exenatide, a GLP-1 receptor agonist, as a potential…

Gamma-Frequency Sensory Stimulation decreases brain atrophy in patients with Alzheimer’s disease

On March 30th 2023 Cognito Therapeutics announced neuroimaging results evaluating the effects of the company’s non-invasive neuromodulation medical device, which delivers proprietary gamma frequency light and sound stimulation in participants with Alzheimer’s disease (AD). The results were presented at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, on March…

Can trichloroethylene (TCE) cause Parkinson’s disease (PD)?

In a paper published online on March 14th 2023 in the Journal of Parkinson’s Disease, researchers suggest that a common chemical, TCE, may be a key reason for the dramatic increase in Parkinson’s disease (PD). Lead investigator Ray Dorsey, MD, professor of neurology, University of Rochester, US has called PD “the world’s fastest-growing brain disease,” and said…

Phase 2 Trial of NLY01 in Parkinson’s Disease: Topline results

 – This randomised, double-blind, placebo-controlled trial was designed to assess the safety, tolerability, and efficacy of NLY01 in subjects with early, untreated PD. – The primary endpoint, change from baseline in the sum of MDS-UPDRS Parts II and III after 36 weeks of NLY01 treatment, compared with placebo, did not reach statistical significance. – Age was identified as a significant…

Vestibular Rehabilitation in Concussion

Clinical Education in concussion at Southampton Football Club Emma Jewer, Concussion Service Lead at Hobbs Rehabilitation, recently delivered 2 workshops with practical and theory sessions to the medical teams from the youth, adult and women’s teams.  This has led to requests for more practical training on baseline testing and embedding this into their existing rehab and…

Effects of median nerve stimulation on Tourette syndrome

Results of UK-wide double-blind sham-controlled clinical trial of the Neupulse device for suppressing tics in Tourette syndrome The trial was run by the University of Nottingham, conducted between 18th March 2022 and 5th of March 2023, sponsored by Nottingham University Hospitals NHS Trust. The aim was to evaluate the effectiveness of the Neupulse device in…

Primary Progressive MS confirmed to be distinct from other MS subtypes

Long suspected by the research community, new study from Tisch MS Research Center of New York, published in Brain, finally establishes that PPMS is pathophysiologically separate from other forms of MS Findings have groundbreaking implications for targeted treatment of PPMS, a disease characterised by worsening neurological function and progressive disability in patients The Tisch MS…

‘Microbot’ development could help treat seizures

University of Glasgow researchers are part of a new project which is setting out to develop tiny injectable robots capable of predicting and mitigating epileptic seizures. The project, called CROSSBRAIN, is led by Tor Vergata University of Rome in Italy and is funded by the European Innovation Council.  Over the course of the next four…